Neurogene (NGNE) Other Non Operating Income (2013 - 2026)
Neurogene's (NGNE) quarterly Other Non Operating Income came in at $163000.0 in Q1 2026, up 10.14% YoY from $148000.0 in Q1 2025, and up 4.49% on a QoQ basis from $156000.0 in Q4 2025.
Powered by 
Analysis
Neurogene (NGNE) Other Non Operating Income (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 12 years of Other Non Operating Income data on file, last reported at $163000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 10.14% year-over-year to $163000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 190.16% YoY) and the FY2025 annual result came in at $1.7 million, up 190.07% from the prior year.
- Other Non Operating Income grew to $163000.0 in Q1 2026, from $156000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $16.4 million in Q4 2023 to a low of $143000.0 in Q1 2024.
- A 4-year average of $1.9 million and a median of $148500.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income tumbled 99.12% — and 2025, when it surged 741.67%.
- Tracing NGNE's Other Non Operating Income over 4 years: stood at $16.4 million in 2023, then plunged by 99.12% to $144000.0 in 2024, then climbed by 8.33% to $156000.0 in 2025, then gained by 4.49% to $163000.0 in 2026.
- The last three Other Non Operating Income figures came in at $163000.0 (Q1 2026), $156000.0 (Q4 2025), and $149000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 143,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 156,000.00 |
| Sep 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 148,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 144,000.00 |
| Mar 31, 2024 | 143,000.00 |
| Dec 31, 2023 | 16.36 Mn |
| Mar 31, 2020 | 15,000.00 |
| Mar 31, 2019 | 2,000.00 |
| Dec 31, 2018 | 1.48 Mn |
| Sep 30, 2018 | -262,000.00 |
| Jun 30, 2018 | -118,000.00 |
| Mar 31, 2018 | -53,000.00 |
| Dec 31, 2017 | 976,000.00 |
| Sep 30, 2017 | 8,000.00 |
| Jun 30, 2017 | -12,000.00 |